Finnish Biotech Secures U.S. Patent for Ivermectin-based Nasal Spray
to Take on COVID-19 in Low-to-Middle-Income Countries (LMICs)
A biotech venture based in Turku, Finland, called Therapeutica Borealis
just secured a patent from the United States Patent and Trademark Office (USPTO) for its COVID-19 therapy
based on ivermectin and a few other notable therapies:
hydroxychloroquine and aprotinin.
Developed as a nasal spray, which can challenge the virus’ ability to enter the body and replicate,
this particular investigational product
can be mass-produced at low cost and distributed to parts around the world where vaccination may be less pervasive.
Now the company
seeks pharmaceutical company partners to scale up research and go-to-market.
This new venture known as Therapeutica Borealis
is affiliated with the University of Turku and is located in Turku, Finland, in the far southwest.
This city of only about 200,000
represents the nation’s top life sciences cluster, which is actually the source of nearly 70% of Finish biopharma exports.
The city has a concentration of over 1,000 researchers distributed over more than 100 research groups making up what’s known as “Health Turku.”
This particular investigational nasal therapeutic product
involves active substances, including aprotinin,
hydroxychloroquine,
and ivermectin,
used in this particular configuration in a targeted manner on the mucous membrane of the upper respiratory tract.
The founders declare that
this targeted use actually allows for lower dosage of the active substances, making the treatment safe and more concentrated for efficacy.
Now the company
seeks pharmaceutical company partners to scale up research and go-to-market.This new venture known as Therapeutica Borealis
is affiliated with the University of Turku and is located in Turku, Finland, in the far southwest.
This city of only about 200,000
represents the nation’s top life sciences cluster, which is actually the source of nearly 70% of Finish biopharma exports.
The city has a concentration of over 1,000 researchers distributed over more than 100 research groups making up what’s known as “Health Turku.”
This particular investigational nasal therapeutic product
involves active substances, including aprotinin,
hydroxychloroquine,
and ivermectin,used in this particular configuration in a targeted manner on the mucous membrane of the upper respiratory tract.
The founders declare that
this targeted use actually allows for lower dosage of the active substances, making the treatment safe and more concentrated for efficacy.